Aeterna Zentaris Inc
F:ET8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aeterna Zentaris Inc
Cash Equivalents
Aeterna Zentaris Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aeterna Zentaris Inc
F:ET8
|
Cash Equivalents
$7.3m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-16%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash Equivalents
CA$86.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash Equivalents
$80.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash Equivalents
$199.2m
|
CAGR 3-Years
52%
|
CAGR 5-Years
35%
|
CAGR 10-Years
13%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Cash Equivalents
$50.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aeterna Zentaris Inc
Glance View
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
What is Aeterna Zentaris Inc's Cash Equivalents?
Cash Equivalents
7.3m
USD
Based on the financial report for Dec 31, 2025, Aeterna Zentaris Inc's Cash Equivalents amounts to 7.3m USD.
What is Aeterna Zentaris Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-16%
Over the last year, the Cash Equivalents growth was -55%. The average annual Cash Equivalents growth rates for Aeterna Zentaris Inc have been -48% over the past three years , -21% over the past five years , and -16% over the past ten years .
